Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d’Enregistrement et Suivi des patients traités par CAR-T cells) registry
Clinical Microbiology and Infection · 2026-02 · 32 (2) · 277-284
DOI: 10.1016/j.cmi.2025.10.005 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Microbiology and Infection, 2026-02. Verfasst von Amélie Bouvier und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Immunology, Henri Mondor Hospital, Créteil, France; Sorbonne University, Paris, France. Hauptthemen laut MEDLINE: Invasive Fungal Infections, Lymphoma, B-Cell, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Novartis.
Abstract (Originalsprache)
OBJECTIVES: To describe the landscape of invasive fungal infections (IFIs) after chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies from the French national DESCAR-T registry and evaluate risk factors associated with invasive fungal infections in this population. METHODS: We conducted a multicentre cohort study to describe the landscape of IFIs in adults with relapsed or refractory B-cell lymphoma treated with CD19 CAR T-cell therapy. Patients were identified through the French DESCAR-T registry. Clinical and biological data were collected retrospectively. Each IFI was classified according to the European Organization for Research and Treatment of Cancer (EORTC) criteria. RESULTS: Among the 1012 patients included in the registry from 2018 to 2022, 32 patients (3.1%) presented with proven (n = 14/32), probable (n = 12/32), or possible (n = 6/32) IFIs. The median time to onset was 29.5 days (IQR 16.5-79.5 days). The most frequent mould infection was invasive aspergillosis, occurring in 11 of 32 patients, whereas the most frequent yeast infection was candidemia occurring in 12 of 32 patients. The IFI-related mortality rate among infected patients was 21.8% (7/32 patients). Multivariate analysis identified several risk factors associated with IFIs: advanced age, number of prior lines of therapy, prior allogeneic haematopoietic cell transplantation, antiinterleukin-1 receptor antagonist treatments, and pre-IFI bacterial infection. The median overall survival of patients with IFIs was 6 months (95% CI, 1.0-20.6) compared with 25.4 months (95% CI, 20.5-32.0) in the noninfected population. The median progression-free survival of patients with IFIs was 3.2 (95% CI, 0.8-18.3) months compared with 5.8 months (95% CI, 4.5-6.7) in the noninfected population. CONCLUSIONS: Despite the low incidence of IFI in B-cell lymphoma patients treated with CD19 CAR T-cell therapy, the high infectious mortality underscore the need for individualized prophylaxis and rapid diagnosis for high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Immunology, Henri Mondor Hospital, Créteil, France; Sorbonne University, Paris, France.
- Clinical Hematology, François Mitterand Hospital, Dijon, France.
- The Lymphoma Academic Research Organisation (LYSARC), Lyon-Sud Hospital, 165 chemin du grand revoyet 69310 Pierre-Benite, France.
- Clinical Hematology, Lille University Hospital, Lille, France.
- Hematological Cancer Unit, Gustave Roussy Institute, Villejuif, France.
- Clinical Hematology, Nancy University Hospital, Nancy, France.
Förderung
- Gilead Sciences
- Novartis
Zitieren
APA
Bouvier, A., Durand, A., Dupont, V., Gower, N., Lorente, C. C., Campidelli, A., Dulery, R., Gangneux, J. P., Joris, M., Eloit, M., Latiere, C., di Blasi, R., Denis, B., Gabellier, L., Morschhauser, F., Casasnovas, O., Houot, R., Angebault, C., Bachy, E., …, & Melica, G. (2026). Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d’Enregistrement et Suivi des patients traités par CAR-T cells) registry. Clinical Microbiology and Infection, 32(2), 277-284. https://doi.org/10.1016/j.cmi.2025.10.005
Vancouver
Bouvier A, Durand A, Dupont V, Gower N, Lorente CC, Campidelli A, et al. Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d’Enregistrement et Suivi des patients traités par CAR-T cells) registry. Clinical Microbiology and Infection. 2026;32(2):277-284. doi:10.1016/j.cmi.2025.10.005
BibTeX
@article{Bouvier2026,
author = {Bouvier, Amélie and Durand, Amandine and Dupont, Vivien and Gower, Nicolas and Lorente, Cristina Castilla and Campidelli, Arnaud and Dulery, Rémi and Gangneux, Jean-Pierre and Joris, Magalie and Eloit, Martin and Latiere, Christelle and di Blasi, Roberta and Denis, Blandine and Gabellier, Ludovic and Morschhauser, Franck and Casasnovas, Olivier and Houot, Roch and Angebault, Cécile and Bachy, Emmanuel and Le Bras, Fabien and Gastinne, Thomas and Tudesq, Jean-Jacques and Lemonnier, François and Melica, Giovanna},
title = {Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d’Enregistrement et Suivi des patients traités par CAR-T cells) registry},
journal = {Clinical Microbiology and Infection},
year = {2026},
volume = {32},
number = {2},
pages = {277--284},
doi = {10.1016/j.cmi.2025.10.005}
}
EUVIMED